JIBTVA  Vol.1 No.2 , July 2012
Telavancin in Experimental Murine Pneumococcal Pneumonia
ABSTRACT
We determined whether telavancin is as active in experimental immunocompetent murine pneumococcal pneumonia as is vancomycin or ceftriaxone. Experimental murine pneumonia was established by intratracheal administration of Streptococcus pneumoniae. Four groups of animals were studied, untreated and treated with vancomycin (110 mg/kg, bid, SQ), telavancin (40 mg/kg, bid, SQ), or ceftriaxone (50 mg/kg, bid, SQ) for 2 days. The untreated animals had a mean of 6.54 ± 0.82 log10 cfu/g lung. The vancomycin-, telavancin-, and ceftriaxone-treated animals had means of 2.01 ± 0.02, 2.00 ± 0.00, and 2.00 ± 0.01 log10 cfu/g lung, respectively (p-values < 0.0001 for each treatment group versus the untreated group). In the model studied, telavancin was as active as vancomycin and ceftriaxone in treating experimental pneumococcal pneumonia in mice.

Cite this paper
S. Schmidt, M. Karau, J. Mandrekar, J. Steckelberg and R. Patel, "Telavancin in Experimental Murine Pneumococcal Pneumonia," Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol. 1 No. 2, 2012, pp. 15-19. doi: 10.4236/jibtva.2012.12003.
References
[1]   M. A. Borg, E. Tiemersma, E. Scicluna, N. Van De Sande-Bruinsma, M. De Kraker, J. Monen and H. Grundmann, “Prevalence of Penicillin and Erythromycin Resistance among Invasive Streptococcus pneumoniae Isolates Reported by Laboratories in the Southern and Eastern Mediterranean Region,” Clinical Microbiology and Infection, Vol. 15, No. 3, 2009, pp. 232-237. doi:10.1111/j.1469-0691.2008.02651.x

[2]   G. R. Corey, M. E. Stryjewski, W. Weyenberg, U. Yasothan and P. Kirkpatrick, “Telavancin,” Nature Reviews Drug Discovery, Vol. 8, 2009, pp. 929-930. doi:10.1038/nrd3051

[3]   J. Bonkowski, A. R. Daniels and W. J. Peppard, “Role of Telavancin in treatment of skin and skin structure infections,” Clinical, Cosmetic and Investigational Dermatology, Vol. 3, 2010, pp. 127-133.

[4]   S. N. Leonard and M. J. Rybak, “Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram-Positive Infections,” Pharmacotherapy, Vol. 28, No. 4, 2008, pp. 458-468. doi:10.1592/phco.28.4.458

[5]   F. Van Bambeke, “Glycopeptides in Clinical Development: Pharmacological Profile and Clinical Perspectives,” Current Opinion in Pharmacology, Vol. 4, No. 5, 2004, pp. 471-478. doi:10.1016/j.coph.2004.04.006

[6]   S. S. Hegde, N. Reyes, R. Skinner and S. Difuntorum, “Efficacy of Telavancin in a Murine Model of Pneumonia Induced by Methicillin-Susceptible Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 1, 2008, pp. 169-172. doi:10.1093/jac/dkm417

[7]   D. C. Draghi, B. M. Benton and K. M. Krause, C. Thornsberry, C. Pillar and D. F. Sahm, “In Vitro Activity of Telavancin against Recent Gram-Positive Clinical Isolates: Results of the 2004-05 Prospective European Surveillance Initiative,” Journal of Antimicrobial Chemo-therapy, Vol. 62, No. 1, 2008, pp. 116-121. doi:10.1093/jac/dkn124

[8]   W. T. Jansen, A. Verel, J. Verhoef and D. Milatovic, “In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe,” Antimicrobial Agents and Chemotherapy, Vol. 51, No. 9, 2007, pp. 3420-3424. doi:10.1128/AAC.00100-07

[9]   Clinical and Laboratory Standards Institute, “Clincal and Laboratory Standards Institute: 2011 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement,” CLSI Document M100-S21, Vol. 31, No. 1.

[10]   Clinical and Laboratory Standards Institute, “Clinical and Laboratory Standards Institute: 2009 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically,” Approved Standard—Eighth Edition CLSI Document M07-A8, Vol. 29, No. 2, 2009, pp. 21- 22.

[11]   B. B. Mook-Kanamori, M. S. Rouse, C. I. Kang, D. Van De Beek, J. M. Steckelberg and R. Patel, “Daptomycin in Experimental Murine Pneumococcal Meningitis,” BMC Infectious Diseases, Vol. 9, No. 50, 2009. doi:10.1186/1471-2334-9-50

[12]   A. L. Esposito and J. E. Pennington, “Experimental Pneumonia due to Haemophilus influenzae: Observations on Pathogenesis and Treatment,” The Journal of Infectious Diseases, Vol. 149, No. 5, 1984, pp. 728-734. doi:10.1093/infdis/149.5.728

[13]   E. Azoulay-Dupuis, J. P. Bedos, E. Vallee, D. J. Hardy, R. N. Swanson and J. J. Pocidalo, “Antipneumococcal Activity of Ciprofloxacin, Ofloxacin, and Temafloxacin in an Experimental Mouse Pneumonia Model at Various Stages of the Disease,” The Journal of Infectious Diseases, Vol. 163, No. 2, 1991, pp. 319-324. doi:10.1093/infdis/163.2.319

[14]   D. Chiavolini, G. Pozzi and S. Ricci, “Animal Models of Streptococcus pneumoniae Disease,” Clinical Microbiology Reviews, Vol. 21, 2008, pp. 666-685. doi:10.1128/CMR.00012-08

[15]   N. Reyes, R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner and S. S. Hegde, “Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus,” Antimicrob Agents Chemother, Vol. 49, No. 10, 2005, pp. 4344- 4346. doi:10.1128/AAC.49.10.4344-4346.2005

[16]   J. L. Crandon, J. L. Kuti and D. P. Nicolau, “Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model,” Antimicrob Agents Chemother, Vol. 54, No. 12, 2010, pp. 5115-5119. doi:10.1128/AAC.00062-10

[17]   M. S. Rouse, M. M. Hein, P. Anguita-Alonso, J. M. Steckelberg and R. Patel, “Ceftobiprole Medocaril (BAL5 788) Treatment of Experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae Murine Pneumonia,” Diagnostic Microbiology and Infectious Disease, Vol. 55, 2006, pp. 333-336. doi:10.1016/j.diagmicrobio.2006.01.029

[18]   P. Moine, E.Vallee, E.Azoulay-Dupuis, P.Bourget, J. P. Bedos, J. Bauchet and J. J. Pocidalo, “In Vivo Efficacy of a Broad-Spectrum Cephalosporin, Ceftriaxone, against Penicillin-Susceptible and -Resistant Strains of Streptococcus pneumoniae in a Mouse Pneumonia Model,” Antimicrob Agents Chemother, Vol. 38, No. 9, 1994, pp. 1953-1958. doi:10.1128/AAC.38.9.1953

[19]   C. Sauve, E. Azoulay-Dupuis, P. Moine, C. Darras-Joly, V. Rieux, C. Carbon and J. P. Bedos, “Efficacies of Cefotaxime and Ceftriaxone in a Mouse Model of Pneu- monia Induced by Two Penicillin- and Cephalosporin-Resistant Strains of Streptococcus pneumoniae,” Antimicrob Agents Chemother, Vol. 40, No. 12, 1996, pp. 2829-2834.

[20]   S. S. Hegde, N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. Mccullough, K. Kaniga, J. Pace, R. Thomas, J. P. Shaw, et al., “Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria,” Antimicrob Agents Chemother, Vol. 48, No. 8, 2004, pp. 3043-3050. doi:10.1128/AAC.48.8.3043-3050.2004

[21]   A. G. Madrigal, L. Basuino and H. F. Chambers, “Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus,” Antimicrob Agents Chemother, Vol. 49, No. 8, 2005, pp. 3163-3165. doi:10.1128/AAC.49.8.3163-3165.2005

[22]   N. Reyes, R. Skinner, B. M. Benton, K. M. Krause, J. Shelton, G. P. Obedencio and S. S. Hegde, “Efficacy of Telavancin in a Murine Model of Bacteraemia Induced by Methicillin-Resistant Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy, Vol. 58, No. 2, 2006, pp. 462-465. doi:10.1093/jac/dkl222

[23]   A. Stucki, P. Gerber, F. Acosta, M. Cottagnoud and P. Cottagnoud, “Efficacy of telavancin against penicillin- resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters,” Antimicrob Agents Chemother, Vol. 50, No. 2, 2006, pp. 770-773. doi:10.1128/AAC.50.2.770-773.2006

[24]   L. Y. Yin, J. H. Calhoun, T. S. Thomas and E. D. Wirtz, “Efficacy of Telavancin in the Treatment of Methicillin-Resistant Staphylococcus aureus Osteomyelitis: Studies with a Rabbit Model,” Journal of Antimicrobial Chemotherapy, Vol. 63, No. 2, 2009, pp. 357-360. doi:10.1093/jac/dkn490

[25]   E. Rubinstein, T. Lalani, G. R. Corey, Z. A. Kanafani, E. C. Nannini, M. G. Rocha, G. Rahav, M. S. Niederman, M. H. Kollef, A. F. Shorr, et al., “Telavancin versus Van- comycin for Hospital-Acquired Pneumonia due to Gram- Positive Pathogens,” Clinical Infectious Diseases, Vol. 52, No. 1, 2011, pp. 31-40. doi:10.1093/cid/ciq031

[26]   M. Venditti, M. Falcone, S. Corrao, G. Licata and P. Serra, “Outcomes of Patients Hospitalized with Community-Acquired, Health Care-Associated, and Hospital- Acquired Pneumonia,” Annals of Internal Medicine, Vol. 150, No. 1, 2009, pp. 19-26.

 
 
Top